The Handoff: Your Week in Endocrinology News - 3/24/17

Share this content:

The Handoff is a weekly roundup of endocrinology and general medicine news covering various developments in subspecialties, as well as pharmaceutical industry, association, and society news.

--Research published in JAMA suggest that diabetic complications and comorbidities are increased in young adults with type 2 vs type 1 diabetes. After adjustment for established risk factors, type 2 diabetes was associated with a significantly increased risk for diabetic kidney disease, retinopathy, and peripheral neuropathy compared with type 1 diabetes.

--Pharmaceutical companies spent over $6 billion on direct-to-consumer television advertising in 2016 — a 5% increased from 2015. The American Medical Association, however, has taken a firm stance in opposition, stating that some advertisements may be driving the demand for costly treatments that may not be more clinically effective than cheaper alternatives.

--A study published in the International Journal of Obesity questions if 15,000 steps should be our new daily exercise target. The study expands upon findings from the London Transit Workers Study.

--Decades-old advice to pregnant mothers — get plenty of rest and eat for 2 — is being challenged as high-quality studies show the safety and efficacy of maternal exercise during pregnancy.

--According to research presented at the 66th Annual Scientific Session & Expo of the American College of Cardiology, patients with diabetes are more likely to experience delayed presentation of symptoms in ST-segment elevation myocardial infarction (STEMI) compared with those without diabetes.

--Research from the European Journal of Endocrinology found that following Roux-en-Y gastric bypass, patients may experience a “progressive deterioration in bone microarchitecture and estimated strength.”

--Expert praise of Repatha® (evolocumab, Amgen), a highly anticipated PCSK9 inhibitor, has been slow to come, according to a piece in the New York Times. While the drug does drastically reduce LDL-cholesterol, the drug's high cost and possible safety issues may not make it a viable option for all patients.

--Climate change may drastically increase cases of type 2 diabetes, according to Dutch investigators, although further research is needed to conclusively determine why the link exists.

--If the eyes are the window to the soul, can a selfie be the window to… a thyroid cancer diagnosis? Actress-producer Lorna Nickson Brown spoke to Teen Vogue about her diagnosis and overlooking a common symptom.

--Data enthusiasts, rejoice: the (costly) practice of wearing a continuous glucose monitor (CGM) — typically the domain of people with type 1 diabetes — has become more common among those without the condition. While there are no negative side effects, no data exists showing that CGM use can improve the health of a person without diabetes.

--The American Thyroid Association (ATA) Spring 2017 Satellite Symposium will examine the effects of hypothyroidism and thyroid hormone therapy on patients, asking the question “Hypothyroidism: Where Are We Now?” The symposium takes place on Friday, March 31st in Orlando, FL.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus